Page 298 - Total War on PTSD

We are studying whether MDMA-assisted psychotherapy can help heal the psychological and emotional damage caused by sexual assault, war, violent crime, and other traumas. We also sponsored completed studies of MDMA-assisted psychotherapy for autistic adults with social anxiety, and MDMA-assisted psychotherapy for anxiety related to life-threatening illnesses.
MAPS is undertaking a roughly $26.9 Million plan to make MDMA into a Food and Drug Administration (FDA) approved prescription medicine by 2021, and is currently the only organization in the world funding clinical trials of MDMA-assisted psychotherapy. For-profit pharmaceutical companies are not interested in developing MDMA into a medicine because the patent for MDMA has expired. The idea of using MDMA to assist psychotherapy of any kind for any specific clinical indication has long been in the public domain.
In MDMA-assisted psychotherapy, MDMA is only administered a few times, unlike most medications for mental illnesses which are often taken daily for years, and sometimes forever. MDMA is not the same as "Ecstasy" or "molly." Substances sold on the street under these names may contain MDMA, but frequently also contain unknown and/or dangerous adulterants. In laboratory studies, pure MDMA has been proven sufficiently safe for human consumption when taken a limited number of times in moderate doses.
Expanded Access is a U.S. FDA program that allows the use of an investigational drug under a Treatment Protocol. The program is designed to address urgent and life-threatening conditions in patients who do not currently have promising treatment options. Only sites within the U.S and U.S. territories are eligible to participate in the U.S. FDA Expanded Access Program. MAPS does not have an Expanded Access program at this time but will be applying to FDA in early
298 of 1042